Compare Icl Group Ltd (ICL) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Eli Lilly And Co — how do they compare? Icl Group Ltd trades at $5.01 (market cap $6.47B), while Eli Lilly And Co trades at $1,169.74 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 160.7× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (4.11%). Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Eli Lilly And Co for 93 Days on average.
| ICL | LLY | |
|---|---|---|
Market Cap | $6.47B | $1.04T |
Volume | 1,387,140 | 3,064,878 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $1.28K |
52-Week Low | $4.80 | $799.57 |
Typical Hold Time | 56 Days | 93 Days |
Enterprise Value | $9.11B | $1.09T |
Dividend Yield | 4.11% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.08 with no daily change, showing stable but muted short-term performance. The stock exhibits bearish technical signals with declining revenue and net income margins over recent years, though Q2 2026 earnings beat expectations. Analyst consensus is entirely neutral with 4 hold ratings and a $6.08 price target, suggesting limited near-term upside. Recent news highlights dividend stability and cost-transformation initiatives amid fertilizer industry headwinds.
ICL faces mixed prospects with stable cash flows and dividend payments offset by profitability pressures. The 19.7% upside to consensus target offers moderate potential, but investors must weigh declining margins against operational efficiency efforts. Key risks include input cost inflation and reduced fertilizer demand, requiring careful monitoring of Q3 2026 results and cost program execution.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
